Product Description
LP-08 (Lipella Pharmaceuticals, Inc., Pittsburgh, PA, USA) are therapeutic ÔÔemptyÕÕ liposomes developed for the intravesical treatment of IC. (Sourced from: https://lipella.com/wp-content/uploads/2019/03/LP08-2-luts2012.pdf)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lipella
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cystitis, Interstitial
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01393223 |
IC/BPS | P2 |
Completed |
Cystitis, Interstitial |
2018-06-14 |
2019-03-19 |
Treatments |